Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Treatments and challenges for bullous pemphigoid

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Patient morbidity and mortality in BP

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

What is Bullous Pemphigoid

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Patient morbidity and mortality in BP

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

What is Bullous Pemphigoid

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

ATAR Çalışması: Kombinasyon Tedavisinde 24 Saatlik Kan Basıncı Kontrolü

ATAR Çalışması: Kombinasyon Tedavisinde 24 Saatlik Kan Basıncı Kontrolü

Wykrycie wirusa polio typu 2 pochodzącego ze szczepionki w próbkach ścieków w Polsce

Wykrycie wirusa polio typu 2 pochodzącego ze szczepionki w próbkach ścieków w Polsce

Poliomyelitis pozostaje istotnym problemem zdrowia publicznego, nawet w krajach od dawna uznawanych za wolne od polio.
Protection Beyond Flu Infografik

Protection Beyond Flu Infografik

Plano de Exercício Sanofi e APCL ultrapassa 200 participações

Plano de Exercício Sanofi e APCL ultrapassa 200 participações

Highlights ATTD 2025

Highlights ATTD 2025

BR1DGE: Eleve o seu conhecimento em DT1 para o próximo nível

BR1DGE: Eleve o seu conhecimento em DT1 para o próximo nível